1.1Complement inhibition with a peptide
A hydrated polymer network releases the peptide into the vitreous by diffusion. The peptide binds C3 and reduces complement activation in eyes with geographic atrophy.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A hydrated polymer network releases the peptide into the vitreous by diffusion. The peptide binds C3 and reduces complement activation in eyes with geographic atrophy.
A sintered alumina membrane admits ocular fluid into the reservoir, where it dissolves crystalline statin. Dissolved statin diffuses out through the same pores at a rate governed by membrane thickness, pore size, and open pore area.
The chamber contains an aqueous statin solution in contact with excess solid statin. Dissolved statin diffuses through the fluid-filled capillary, and the bore diameter and channel length set the diffusional resistance.
Ocular fluid permeates the membrane and dissolves statin at the core surface. Dissolved statin partitions into the membrane and diffuses outward at a rate governed by membrane thickness and permeability.
A pump chamber draws an aqueous statin formulation from a sealed reservoir and discharges it through an ocular outlet. The volume displaced per stroke and the number of strokes per day determine the delivered volume.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A thin strip of polycaprolactone contains dispersed simvastatin particles. The strip sits below the gum line in a periodontal pocket with both faces exposed to gingival crevicular fluid. The polymer matrix limits fluid access to the drug particles and controls statin release into the pocket.
A crosslinked poly(dimethylsiloxane) elastomer forms the matrix of a flat ocular insert. Micronized simvastatin is mixed into the uncured elastomer, and the mixture is cast and cured in a flat mold. Dissolved statin partitions into the silicone and diffuses to the exposed surfaces, where it transfers into the surrounding fluid.
Two disk-shaped ocular implant prototypes are cast from the same polycaprolactone and simvastatin dispersion. Each disk is 2 mm across, with one cast to 50 μm thick and the other to 150 μm thick. Fluid contacts both faces of each disk during release testing, giving nominal center-to-face diffusion distances of 25 μm and 75 μm, respectively. The resulting release profiles show how matrix thickness changes release timing at a fixed drug concentration in the polymer.
A flat ocular insert has two bonded layers made from the same polymer, with simvastatin dispersed in each layer. The first layer contains 8 wt % simvastatin and the second contains 2 wt %, measured against the dry mass of each layer. Two successive casts form the stack, with the second cast applied after the first layer sets and before it dries fully. With both faces exposed to fluid, the loading difference creates different initial drug concentration gradients at the two faces, and the matrix controls diffusion from each layer.
A statin-loaded polycaprolactone film is fitted around a haptic of an intraocular lens. The film forms a sleeve on the outer segment of the haptic, leaving the optical surfaces exposed. The haptic retains the sleeve in the capsular bag, where fluid contacts the exposed polymer surface and the matrix controls statin release.
A metering pump delivers a suspension of micronized statin in a polymer solution to a motorized casting blade. The blade spreads the suspension onto a removable carrier, and solvent evaporation leaves the statin dispersed in the solid film. A laser displacement sensor measures dry film thickness against the carrier surface. A controller uses the measured thickness to adjust the blade gap for the next pass, and a die cuts ocular inserts from the dried film.
Micronized atorvastatin calcium is suspended in a solution of poly(lactic-co-glycolic acid). The suspension is cast in a cylindrical mold and dried to form a solid rod containing statin particles.
Simvastatin powder is mixed into an uncured medical-grade silicone elastomer. The mixture is molded into a thin disk and cured to immobilize the particles within the cross-linked matrix.
Statin particles are distributed throughout a poly(lactic-co-glycolic acid) implant. Water penetrates the matrix and cleaves ester bonds, opening pathways through which dissolved statin diffuses.
An aqueous solution of pravastatin sodium is mixed with a polyethylene glycol precursor before cross-linking. The statin diffuses through the hydrated network, and cross-link density and implant thickness govern the release profile.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In certain embodiments, the present disclosure relates to pharmaceutical compositions for treating an ocular condition, comprising: a biodegradable polymer matrix and at least one therapeutic agent.B · US 2020/0230157 A1 · ¶ 13
An aspect of the present invention relates to combining the HMG-CoA reductase inhibitor and pFOX inhibitor in a single tablet with a dual delivery system which immediately releases the statin and sustained-releases the pFOX inhibitor.A · US 2011/0275649 A1 · ¶ 11
In another embodiment, the disclosure provides for a method of treating an ocular condition in a subject in need thereof comprising: a) administering at least one intravitreal implant to the posterior of said subject's eye, wherein said intravitreal implant comprises a biodegradable polymer matrix and at least one corticosteroid homogeneously dispersed therein, wherein the intravitreal implant releases the corticosteroid for at least about 4 months (e.g., about 4 months, abouB · US 2020/0230157 A1 · ¶ 71
An empty cell means only that no passage was reproduced there.
The present invention relates to the newly recognized problem of statin induced diabetes.A · US 2011/0275649 A1 · ¶ 6
The present invention concerns a unit dose combination comprising HMG CoA reductase, such as statin and pFOX inhibitor to prevent or reduce the risk of developing diabetes in statin therapy.A · US 2011/0275649 A1 · ¶ 6
Therefore, there is a great need in the medical field for an alternative treatment using a sustained-release delivery system with an improved safety and efficacy profile.B · US 2020/0230157 A1 · ¶ 6
Moreover, the present disclosure provides implants with highly uniform, tunable and reproducible size, shape, loading, composition, and load distribution, which provide implants having a desired extended drug release profile suitable for treating desired indications.B · US 2020/0230157 A1 · ¶ 8
patent.fyi, US 2026/0355154 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355154/, SHA-256 4e6c387b419573de3315d0d3a948a027c105bdbc32b26929182e755ef9b91467